百济神州,迎来历史性时刻。近期,百济神州A股市值突破3107亿,其以27亿元的微弱优势超越传统巨头恒瑞医药,晋升为新的“医药一哥”。过去,恒瑞医药以“仿制+创新”齐头并进的模式稳坐医药“一哥”宝座数年,但在医药周期之下,恒瑞医药开始被创新药龙头百济神州超越。实际上,超越的背后是技术带来的变革。成立于2010年的百济神州前景广阔。在药企普遍采用“仿制+创新”模式的背景下,百济神州却通过“创新+全球化...
Source Link百济神州,迎来历史性时刻。近期,百济神州A股市值突破3107亿,其以27亿元的微弱优势超越传统巨头恒瑞医药,晋升为新的“医药一哥”。过去,恒瑞医药以“仿制+创新”齐头并进的模式稳坐医药“一哥”宝座数年,但在医药周期之下,恒瑞医药开始被创新药龙头百济神州超越。实际上,超越的背后是技术带来的变革。成立于2010年的百济神州前景广阔。在药企普遍采用“仿制+创新”模式的背景下,百济神州却通过“创新+全球化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.